Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases

Meng Wang; Adeline Dehlinger; Camila Fernández Zapata; Maya Golan; Gerardina Gallaccio; Leif E Sander; Stephan Schlickeiser; Desiree Kunkel; Tanja Schmitz-Hübsch; Birgit Sawitzki; Arnon Karni; Julian Braun; Lucie Loyal; Andreas Thiel; Judith Bellmann-Strobl; Friedemann Paul; Lil Meyer-Arndt; Chotima Böttcher

doi:10.1038/s41467-023-43553-z

Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases

Nat Commun. 2023 Nov 25;14(1):7728. doi: 10.1038/s41467-023-43553-z.

Authors

Meng Wang^{1

2

3}, Adeline Dehlinger^{1

2

3}, Camila Fernández Zapata^{1

2

3}, Maya Golan⁴, Gerardina Gallaccio^{1

2

3}, Leif E Sander⁵, Stephan Schlickeiser⁶, Desiree Kunkel⁷, Tanja Schmitz-Hübsch^{1

2

3

8}, Birgit Sawitzki⁹, Arnon Karni^{4

10}, Julian Braun^{11

12}, Lucie Loyal^{11

12}, Andreas Thiel^{11

12}, Judith Bellmann-Strobl^{1

2

3}, Friedemann Paul^{1

2

3

8

13}, Lil Meyer-Arndt^{8

11

13}, Chotima Böttcher^{14

15

16}

Affiliations

¹ Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
² Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
³ Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
⁴ Neuroimmunology and Multiple Sclerosis Unit and Laboratory, Sourasky Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
⁵ Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
⁶ Institute of Medical Immunology, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, and Berlin Institute of Health Berlin, Berlin, Germany.
⁷ Flow&MassCytometry Core Facility, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁸ Neuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
⁹ Translational Immunology, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
¹⁰ Faculty of Medicine and Sagol School of Neuroscience Tel Aviv University, Tel Aviv, Israel.
¹¹ Si-M / "Der Simulierte Mensch" a science framework of Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
¹² Berlin Institute of Health (BIH) at Charité-Universitätsmedizin Berlin, Immunomics-Regenerative Immunology and Aging, Berlin, Germany.
¹³ Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
¹⁴ Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany. [email protected].
¹⁵ Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. [email protected].
¹⁶ Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. [email protected].

Abstract

Disease-modifying therapies (DMTs) are widely used in neuroimmunological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Although these treatments are known to predispose patients to infections and affect their responses to vaccination, little is known about the impact of DMTs on the myeloid cell compartment. In this study, we use mass cytometry to examine DMT-associated changes in the innate immune system in untreated and treated patients with MS (n = 39) or NMOSD (n = 23). We also investigated the association between changes in myeloid cell phenotypes and longitudinal responsiveness to homologous primary, secondary, and tertiary SARS-CoV-2 mRNA vaccinations. Multiple DMT-associated myeloid cell clusters, in particular CD64⁺HLADR^low granulocytes, showed significant correlations with B and T cell responses induced by vaccination. Our findings suggest the potential role of myeloid cells in cellular and humoral responses following vaccination in DMT-treated patients with neuroimmunological diseases.

MeSH terms

Antibodies, Viral
Granulocytes
Humans
Multiple Sclerosis* / drug therapy
Myeloid Cells
Myeloid Progenitor Cells
Neuromyelitis Optica*
Vaccination

Substances

Antibodies, Viral